- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Beth Wittmer on Educating Patients on Neutropenia as a Side of Effect of Cancer Treatment
As patients start chemotherapy to treat their cancer, they are educated on the side effects, particularly neutropenia, said Beth Wittmer, RN, OCN, manager of care management at Florida Cancer Specialists and Research Institute.
As patients start chemotherapy to treat their cancer, they are educated on the side effects, particularly neutropenia, said Beth Wittmer, RN, OCN, manager of care management at Florida Cancer Specialists and Research Institute.
Transcript
How are patients educated on the risk of neutropenia when they’re treated for cancer?
Any patient coming to Florida Cancer Specialists does education prior to starting or on the day of starting their chemotherapy, but there are many that are oral patients that maybe don’t ever go into a treatment room.
So, our care management department helps manage all of those patients, and with that we talk about the side effects of chemotherapy, with neutropenia being one of the most potentially lethal to them. So, we talk about those precautions and we sort of have templates built, as well as patients calling in after hours, and we have a neutropenia protocol that we follow, as well.
STEER Data Open Door to SMA Gene Therapy for Wider Age Range of Children
March 19th 2025Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular atrophy (SMA) aged 2 to 17 years, who had previously been shut out of receiving gene therapy.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More
